Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Senators Circulate Plan For Stand-alone FDA Diagnostics Center, ‘In Vitro Clinical Test’ Rules

This article was originally published in The Pink Sheet Daily

Executive Summary

Senators are drafting legislation to create a stand-alone FDA Center to oversee diagnostics, including IVDs and LDTs, under a framework distinct from current medical device regulations.

You may also be interested in...



Cures Excitement May Wane While Senate Works

Senate Health Committee continues work on its own 21st Century Cures-related legislation, meaning the newly passed House bill will be out of the spotlight for a bit.

FDA Releases LDT Regulatory Framework, Notification Draft Guidances

Two promised draft guidances on FDA’s framework for regulating laboratory developed tests and notification and medical device reporting requirements for LDTs have been posted. The agency wants swift notification from labs for most available LDTs once a framework is finalized.

Senate Bill Would Create New Diagnostics Center At FDA

A bill under development by Sen. Orrin Hatch, R-Utah, would carve out a new center at FDA for regulating all advanced diagnostics, according to stakeholders familiar with recent versions of the draft legislation.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS078618

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel